Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)- T Cell Therapy: A Shifting Landscape
Viruses · 24.03.2024 · 16 (4) · 498
DOI: 10.3390/v16040498 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 24.03.2024. Verfasst von Eleftheria Kampouri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland. Hauptthemen laut MEDLINE: Herpesvirus 6, Human, Hematopoietic Stem Cell Transplantation, Virus Activation, Roseolovirus Infections. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant (HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following HCT and is associated with pleiotropic manifestations in this setting, including graft-versus-host disease, myelosuppression, pneumonitis, and CMV reactivation, although the causal link is not always clear. When the virus inserts its genome in chromosomes of germ cells, the chromosomally integrated form (ciHHV6) is inherited by offspring. The condition of ciHHV6 is characterized by the persistent detection of HHV-6 DNA, often confounding diagnosis of reactivation and disease—this has also been associated with adverse outcomes. Recent changes in clinical practice in the field of cellular therapies, including a wider use of post-HCT cyclophosphamide, the advent of letermovir for CMV prophylaxis, and the rapid expansion of novel cellular therapies require contemporary epidemiological studies to determine the pathogenic role and spectrum of disease of HHV-6B in the current era. Research into the epidemiology and clinical significance of HHV-6B in chimeric antigen receptor T cell (CAR-T cell) therapy recipients is in its infancy. No controlled trials have determined the optimal treatment for HHV-6B. Treatment is reserved for end-organ disease, and the choice of antiviral agent is influenced by expected toxicities. Virus-specific T cells may provide a novel, less toxic therapeutic modality but is more logistically challenging. Preventive strategies are hindered by the high toxicity of current antivirals. Ongoing study is needed to keep up with the evolving epidemiology and impact of HHV-6 in diverse and expanding immunocompromised patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.
- Department of Medicine, Division of Infectious Disease and International Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
- Department of Medicine, University of Washington, Seattle, WA 98195, USA.
ORCID-Profile: Eleftheria Kampouri, Guy Handley, Joshua A Hill
Zitieren
APA
Kampouri, E., Handley, G., & Hill, J. A. (2024). Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)- T Cell Therapy: A Shifting Landscape. Viruses, 16(4), 498. https://doi.org/10.3390/v16040498
Vancouver
Kampouri E, Handley G, Hill JA. Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)- T Cell Therapy: A Shifting Landscape. Viruses. 2024;16(4):498. doi:10.3390/v16040498
BibTeX
@article{Kampouri2024,
author = {Kampouri, Eleftheria and Handley, Guy and Hill, Joshua A},
title = {Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)- T Cell Therapy: A Shifting Landscape},
journal = {Viruses},
year = {2024},
volume = {16},
number = {4},
pages = {498},
doi = {10.3390/v16040498}
}
EUVIMED